Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Forest Laboratories’ Lexapro is no longer the leading first-line agent of choice for the treatment of major depression.
Popularity: unranked [?]
Related posts:
- Lexapro Loses First-Line Position For The Treatment Of Major Depression
- Current And Emerging Drugs Continue To Struggle For Patient Share In The Treatment Of Major Depressive Disorder
- Major Depression Prevalence Is Closely Correlated With Ethnic Status In The U.S.
- Forest Laboratories, Inc. Announces FDA Approval Of Lexapro(R) For The Treatment Of Major Depressive Disorder In Adolescents
- Forest Laboratories, Inc. Announces Positive Results Of LEXAPRO(R) Phase III Study In Adolescents With Major Depression
Comments
No Responses to “Lexapro Loses First-Line Position For The Treatment Of Major Depression”